Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 100

Licensing Licensing Engineering Therapies 100

BioPharma Drive: Drug Pricing

FEBRUARY 1, 2024

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing 116

Licensing Licensing Production Drugs 116

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing 100

Licensing Licensing Science Research 100

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 100

Licensing Licensing Vaccine DNA 100

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.

Licensing 72

Licensing Licensing Treatment Disease 72

BioPharma Drive: Drug Pricing

NOVEMBER 19, 2024

Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug. The agency turned back Astellas’ attempt to update its drug Izervay’s labeling.

Licensing 59

Licensing Licensing FDA Drugs 59

Drug Patent Watch

JULY 26, 2023

While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out that they keep a list on their website, so I… The post List of NIH-Licensed Technologies appeared first on DrugPatentWatch - Make Better Decisions.

Licensing 52

Licensing Licensing 52

Reprocell

SEPTEMBER 19, 2024

The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.

Licensing 59

Licensing Licensing Regulations FDA 59

Drug Patent Watch

AUGUST 6, 2024

Introduction to Pharmaceutical Licensing In the fast-paced world of pharmaceuticals, innovation is the lifeblood that keeps the industry pumping. […] Source

Licensing 52

Licensing Licensing Pharmaceuticals 52

BioPharma Drive: Drug Pricing

DECEMBER 2, 2024

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

Licensing 116

Licensing Licensing Drugs 116

BioPharma Drive: Drug Pricing

NOVEMBER 13, 2023

With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

Licensing 80

Licensing Licensing Therapies 80

BioPharma Drive: Drug Pricing

JULY 3, 2024

The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

Vaccine 72

Vaccine Licensing Licensing 72

Perficient: Drug Development

OCTOBER 20, 2023

While it proved to be tricky to find an opening for an infant, we endeavored to compare in-home daycares and licensed facilities. In contrast, the licensed facilities we used maintained extended afternoon hours, providing a tad more flexibility for evening pickups. Luckily, Perficient is very family friendly.

Licensing 52

Licensing Licensing Doctors Regulations 52

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing 45

Licensing Licensing Pharmacy Regulations 45

Perficient: Drug Development

AUGUST 13, 2024

Cost Management and Optimization One of the key advantages of cloud migration is the potential for significant cost savings and licensing cost avoidance. Our team continuously monitors and optimizes your infrastructure, helping you to maximize the return on your cloud investment.

Licensing 52

Licensing Licensing 52

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Therapies 119

Therapies Licensing Licensing Treatment 119

BioPharma Drive: Drug Pricing

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing 119

Licensing Licensing Drugs 119

BioPharma Drive: Drug Pricing

FEBRUARY 8, 2024

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.

Therapies 116

Therapies Licensing Licensing 116

Drug Discovery Today

MAY 22, 2020

CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield

Licensing 100

Licensing Licensing 100

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research 123

Drug Research Licensing Licensing Research 123

Drug Patent Watch

DECEMBER 10, 2024

“Patent thickets can lead to holdup of innovations, increases in the complexity of negotiations over licenses and increases in litigation, and can also create incentives to add more and weaker patents to the patent system. Cross-licensing agreements: To navigate patent thickets, many companies enter into cross-licensing agreements.

Licensing 98

Licensing Licensing International Marketing 98

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Licensing 69

Licensing Licensing Regulations Drugs 69

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing 64

Licensing Licensing Disease Drugs 64

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Licensing 59

Licensing Licensing Drugs Therapies 59

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 59

Licensing Licensing Pharma Companies Treatment 59

Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons Attribution 4.0

Production 105

Production Pharmaceuticals Licensing Licensing 105

BioPharma Drive: Drug Pricing

JUNE 8, 2023

Two-year-old Kate Therapeutics is launching publicly with $51 million in funding and a licensing deal with Astellas Pharma for a neuromuscular disease gene therapy.

Therapies 98

Therapies Disease Licensing Licensing 98

Drug Discovery Today

NOVEMBER 11, 2022

Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

Licensing 100

Licensing Licensing Drugs Research 100

Crown Bioscience

MAY 2, 2024

This post delves into some frequently asked questions about Omni Screen ™ and its unique capabilities in providing compliant, large-scale cell line screening solutions that are not only cutting-edge but also aligned with industry standards and regulations.

Licensing 52

Licensing Licensing Research Regulations 52

Drug Patent Watch

FEBRUARY 3, 2021

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve….

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

addgene Blog

FEBRUARY 1, 2024

Addgene is excited to announce we now offer an export license application for rabies materials! The export license, if granted, allows us to ship rabies plasmids and viral vectors containing genetic elements from rabies plasmids to international requestors. We also offer export license applications for VSV and SARS-COV-1 plasmids.

Licensing 72

Licensing Licensing International 72

BioPharma Drive: Drug Pricing

JULY 10, 2023

The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.

Therapies 91

Therapies Licensing Licensing 91

Conversations in Drug Development Trends

OCTOBER 26, 2022

That’s because psychedelic trials are logistically heavy, requiring special licensing for drug handling, training for staff in Schedule I drug requirements, and standardized facilities. Certain licensing must be obtained. More guidance on safety considerations can be found, here.

Trials 97

Trials Clinical Trials Licensing Licensing 97

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 52

Licensing Licensing Production Marketing 52

Drug Discovery Today

DECEMBER 17, 2019

s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Bridge currently intends to seek approval from the U.S.

Production 100

Production Licensing Licensing Treatment 100

ASPET

OCTOBER 12, 2023

The Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) program within the JPM Medical is designed to rapidly tackle known, unknown, and emerging threats by utilizing late-stage or licensed therapeutics. Repurposing is one such method.

Therapies 100

Therapies Licensing Licensing FDA Approval 100

BioPharma Drive: Drug Pricing

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing 78

Licensing Licensing Drugs 78